Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 6:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cornea Ectasia Clear all
Not listed Phase 3 Interventional Accepts healthy volunteers

Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Riboflavin/Dextran or Riboflavin/Methylcellulose

NCT04897503
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin
Drug
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
12 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 20, 2026, 6:47 AM EDT
Recruiting Phase 1 Interventional

Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking

NCT03918408
View directory record Official record
Conditions
Keratoconus, Unstable, Bacterial Keratitis, Ectasia of Cornea
Interventions
PXL-330 Platinum device for crosslinking with Peschke ribofflavin solution
Combination Product
Lead sponsor
Pacific Clear Vision Institute
Other
Eligibility
12 Years to 45 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 20, 2026, 6:47 AM EDT
Terminated Phase 3 Interventional

Safety & Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery

NCT01459679
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
KXL System (15 mW/cm2), KXL System (30 mW/cm2), KXL System (45 mW/cm2), riboflavin ophthalmic solution
Device · Drug
Lead sponsor
American-European Congress of Ophthalmic Surgery
Network
Eligibility
12 Years and older
Enrollment
1,721 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 71 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 20, 2026, 6:47 AM EDT
Not listed Phase 1 Interventional

Study of the Safety and Effectiveness of Collagen Cross-Linking at an Irradiance of 9 mW/cm2 and 18 mW/cm2

NCT02009709
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin 0.1% ophthalmic solution, CCL-VARIO UV lamp, CCL-VARIO at 18 mW/cm2
Drug · Device
Lead sponsor
Robert Mack, M.D.
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Hoffman Estates, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 20, 2026, 6:47 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Treatment of Keratoconus Using Collagen Cross-Linking

NCT00841386
View directory record Official record
Conditions
Keratoconus
Interventions
Riboflavin-5-phosphate, Sham cross-linking
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
16 Years to 35 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Amherst, New York • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2009 · Synced Sep 20, 2026, 6:47 AM EDT
Terminated Phase 2 Interventional

Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross-Linking in Eyes With Keratoconus.

NCT02762253
View directory record Official record
Conditions
Keratoconus
Interventions
Riboflavin drops
Drug
Lead sponsor
Nvision Laser Eye Centers
Industry
Eligibility
12 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
11
States / cities
Camarillo, California • Citrus Heights, California • Fullerton, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Sep 20, 2026, 6:47 AM EDT
Not listed No phase listed Observational

Observational Registry to Assess the Durability of Effect of CXL in Patients With Corneal Ectasia After Refractive Surgery

NCT03319082
View directory record Official record
Conditions
Corneal Ectasia
Interventions
Corneal Collagen Cross-linking
Combination Product
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
11
States / cities
Palo Alto, California • Bloomington, Minnesota • Bozeman, Montana + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Sep 20, 2026, 6:47 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Effectiveness Study of the VEGA UV-A System for Cross-linking in Eyes With Keratoconus and Ectasia

NCT01398852
View directory record Official record
Conditions
Keratoconus and Ectasia
Interventions
Riboflavin, VEGA UV-A Illumination System
Drug · Device
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
12 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
13
States / cities
Phoenix, Arizona • Atlanta, Georgia • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Sep 20, 2026, 6:47 AM EDT
Not listed Phase 3 Interventional

Transepithelial Corneal Collagen Crosslinking for Keratoconus and Corneal Ectasia

NCT01464268
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin
Drug
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 20, 2026, 6:47 AM EDT
Not listed Phase 3 Interventional

Corneal Collagen Crosslinking and Intacs for Keratoconus and Ectasia

NCT01112072
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin
Drug
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
21 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 20, 2026, 6:47 AM EDT
Terminated No phase listed Observational

Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas

NCT01024322
View directory record Official record
Conditions
Keratoconus, Ectasia, Degeneration
Interventions
Ciprofloxicine or Vigamox or other., Nonsteroidal (Acular, Voltaren Xibrom, etc), Steroid (FML, Pred Forte, Flarex, etc.)
Drug
Lead sponsor
Cxlusa
Industry
Eligibility
8 Years and older
Enrollment
1,189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
Miami, Florida • Rockville, Maryland • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 20, 2026, 6:47 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Wavefront Guided Scleral Lenses for Keratoconus and Irregular Astigmatism

NCT04698590
View directory record Official record
Conditions
Keratoconus, Irregular Astigmatism, Corneal Ectasia, Aberration, Corneal Wavefront, Wavefront Aberration, Corneal, Pellucid Marginal Corneal Degeneration, Keratoglobus
Interventions
Wavefront Guided Scleral Lenses, Traditional Scleral Lenses
Device
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Sep 20, 2026, 6:47 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Dietary Riboflavin (Vitamin B-2) and Cornea Cross-Linking

NCT03095235
View directory record Official record
Conditions
Keratoconus, Cornea Ectasia
Interventions
Dietary riboflavin
Dietary Supplement
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 20, 2026, 6:47 AM EDT
Recruiting Phase 3 Interventional

Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases

NCT07124910
View directory record Official record
Conditions
Keratoconus, Ectasia of Cornea, Pellucid Marginal Corneal Degeneration, Forme Fruste Keratoconus (FFK)
Interventions
Epi-ON corneal cross-linking
Combination Product
Lead sponsor
Woolfson Eye Institute
Other
Eligibility
8 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
12
States / cities
Atlanta, Georgia • Canton, Georgia • Cumming, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 20, 2026, 6:47 AM EDT
Completed Phase 2 Interventional Results available

Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia

NCT01143389
View directory record Official record
Conditions
Keratoconus, Post-Refractive Ectasia
Interventions
Riboflavin, UVX light
Drug · Device
Lead sponsor
Price Vision Group
Industry
Eligibility
10 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 20, 2026, 6:47 AM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Corneal Crosslinking in Keratoconus and Corneal Ectasia

NCT00679666
View directory record Official record
Conditions
Progressive Keratoconus, Corneal Ectasia
Interventions
Riboflavin, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
Columbus, Ohio • Dublin, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 20, 2026, 6:47 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia

NCT01325298
View directory record Official record
Conditions
Keratoconus, Ectasia, Corneal Ectasia
Interventions
UV-X Light, Riboflavin
Device · Drug
Lead sponsor
Mercy Center for Corrective Eye Surgery
Other
Eligibility
14 Years to 55 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
McHenry, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Sep 20, 2026, 6:47 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Corneal Elastography and Patient Specific Modeling

NCT03030755
View directory record Official record
Conditions
Cornea; Ectasia, Refractive Errors, Keratoconus
Interventions
Optical coherence tomography
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
16 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 20, 2026, 6:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution

NCT04667572
View directory record Official record
Conditions
Keratoconus, Pellucid Marginal Corneal Degeneration, Corneal Degeneration, Corneal Ectasia
Interventions
PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Combination Product
Lead sponsor
Cornea Associates of Texas
Other
Eligibility
8 Years and older
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 20, 2026, 6:47 AM EDT
Completed Phase 3 Interventional Results available

Corneal Collagen Cross-Linking for Ectasia (CXL)

NCT00674661
View directory record Official record
Conditions
Ectasia
Interventions
riboflavin ophthalmic solution, UVA Irradiation
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
14 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
10
States / cities
La Jolla, California • San Diego, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Sep 20, 2026, 6:47 AM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of the PXL Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Position

NCT04213885
View directory record Official record
Conditions
Keratoconus, Unstable, Ectasia Corneal, Bacterial Keratitis
Interventions
PXL 330 Platinum device/Riboflavin
Combination Product
Lead sponsor
Eye Specialists of Indiana
Other
Eligibility
12 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Sep 20, 2026, 6:47 AM EDT
Withdrawn Not applicable Interventional

Higher Irradiance in Keratoconus Ectasia

NCT01789333
View directory record Official record
Conditions
Keratoconus, Ectasia
Interventions
UVA Light with irradiance exposure of 9 mW/cm2, Riboflavin 0.1% ophthalmic solution
Device · Drug
Lead sponsor
Stephen Trokel
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 20, 2026, 6:47 AM EDT
Not listed Phase 3 Interventional

Corneal Cross-Linking Comparing Variables

NCT02095730
View directory record Official record
Conditions
Unstable Corneas
Interventions
Epithelium-On Riboflavin, Epithelium-Off Riboflavin, UV Light - Continuous Beam, UV Pulsed Beam
Drug · Device
Lead sponsor
Crowd Health Research, LTD
Other
Eligibility
12 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
16
States / cities
Santa Rosa, California • Denver, Colorado • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2014 · Synced Sep 20, 2026, 6:47 AM EDT
Not listed Phase 3 Interventional

Corneal Collagen Cross-Linking (CXL) Performed With "Epi-ON" Versus "Epi-OFF" in Eyes With Keratoconus and Other Corneal Ectatic Disorders

NCT03858036
View directory record Official record
Conditions
Keratoconus, Ectasia
Interventions
Ricrolin+, VEGA UV-A system
Drug · Device
Lead sponsor
Center for Sight, Sacramento, CA
Other
Eligibility
12 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Sep 20, 2026, 6:47 AM EDT